Eli Lilly’s (LLY) neuroscience product portfolio includes the drugs Cymbalta, Strattera, and Zyprexa—all of which reported sales declines for 3Q17.
Cymbalta, an antidepressant, reported revenues of $183.2 million during 3Q17, representing a 42% YoY (year-over-year) fall in sales, compared with $313.5 million in 3Q16. This decline was driven by an 88% fall in US sales to $19.6 million, offset by an 8% rise in non-US sales to $163.5 million. Non-US sales reported a 13% rise at constant exchange rates, offset by a -5% impact of foreign exchange.
Strattera, a drug for hyperactivity disorder and attention-deficit disorder, reported revenues of $137 million during 3Q17, representing a 31% fall in revenues, compared with $199 million in 3Q16. This fall was driven by a 56% decline in US sales, offset by a 6% rise in non-US sales in 3Q17.
Zyprexa, an antipsychotic drug, reported revenues of $141 million during 3Q17, representing a 6% fall in revenues, compared with $149 million in 3Q16. This decline was driven by a 10% fall in non-US sales, which was partially offset by a 72% rise in US sales to $12.6 million. The decline in non-US revenues was due to competition from other products.